AKTS (Aktis Oncology) Issuance of Debt: $0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AKTS Aktis Oncology Inc AKTS
10 GF Score
Price $25.01
! 1 Warning Sign
View Full Analysis

What is Aktis Oncology Issuance of Debt?

Aktis Oncology AKTS +0.08% 10 Issuance of Debt is $0.00 Mil as of Jun. 2026. GuruFocus rates AKTS with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

Aktis Oncology's Issuance of Debt for the three months ended in Jun. 2026 was $0.00 Mil.

Aktis Oncology's Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00 Mil.

Aktis Oncology Issuance of Debt Related Terms

Aktis Oncology Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Aktis Oncology's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aktis Oncology Issuance of Debt Chart

Aktis Oncology Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Issuance of Debt
0.00 0.00 0.00 0.00

Aktis Oncology Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
AKTS
10GF Score
Aktis Oncology Inc AKTS
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aktis Oncology Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of $0.00 Mil mean?
Aktis Oncology (AKTS) has a Issuance of Debt of $0.00 Mil as of Jun. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Aktis Oncology and its competitors.
Is Aktis Oncology's Issuance of Debt too high?
Aktis Oncology's current Issuance of Debt is $0.00 Mil. Overall, Aktis Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Aktis Oncology's Issuance of Debt compare to ABSI and MNKD?
Aktis Oncology's Issuance of Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Biotechnology company?
A good Issuance of Debt depends on the Biotechnology industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Aktis Oncology and its competitors. Aktis Oncology's current Issuance of Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aktis Oncology stock overvalued right now?
Aktis Oncology (AKTS) has a current Issuance of Debt of $0.00 Mil. The current Issuance of Debt is $0.00 Mil. Aktis Oncology's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Aktis Oncology (AKTS), the current Issuance of Debt is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aktis Oncology Business Description

Address 17 Drydock Avenue, Suite 17-401, Boston, MA, USA, 02210
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
10GF Score

Get the complete analysis for AKTS

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.01
Price